ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2021
Performance of VITEK 2, E-test, Kirby-Bauer disk diffusion, and modified Kirby-Bauer disk diffusion compared to reference broth microdilution for testing tigecycline susceptibility of carbapenem-resistant K. pneumoniae and A. baumannii in a multicenter study in China.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 52 citations in OpenAlex.
- Magnetic nanocrystalline cellulose-poly(methacrylic acid-RSC advances · 2026Article
- Article
- A Cross-Sectional Study to DetermineBioMed research international · 2026Article
- Whole genome sequencing and genomic characterization of the extensively drug-resistant Acinetobacter baumannii recovered from clinical samples in Lahore, Pakistan.Molecular biology reports · 2025Article
- Encapsulation of Hydrogen Peroxide in PVA/PVP Hydrogels for Medical Applications.Gels (Basel, Switzerland) · 2025Article
- New Option for Antibiotic Susceptibility Testing in Clinical Practice: Performance Evaluation of AutoMic-i600 Automatic System Based on Broth Microdilution Method.Infection and drug resistance · 2025Article
- Article
- Detecting antibiotic resistance: classical, molecular, advanced bioengineering, and AI-enhanced approaches.Frontiers in microbiology · 2025Review
- Article
- Mechanisms of Antimicrobial Resistance inInfection and drug resistance · 2025Review
- Green synthesis of silver nanoparticles fromHeliyon · 2024Article
- MALDI-TOF MS combined with AUC method for tigecycline susceptibility testing inJAC-antimicrobial resistance · 2024Article
- Predictors of antibiogram performance and antibiotic resistance patterns in the northern Syrian region: A cross-sectional investigation.Exploratory research in clinical and social pharmacy · 2024Article
- Lactobacillus paracasei R3 Alleviates Tumor Progression in Mice with Colorectal Cancer.Current microbiology · 2023Article
- Clinical efficacy and safety of tigecycline based on therapeutic drug monitoring for carbapenem-resistant Gram-negative bacterium pneumonia in intensive care units.BMC infectious diseases · 2023Article
- Characterization and Molecular Mechanism of Aminoglycoside-6-Adenyl Transferase Associated with Aminoglycoside Resistance fromInfection and drug resistance · 2023Article
- The optimized carbapenem inactivation method for objective and accurate detection of carbapenemase-producingFrontiers in microbiology · 2023Article
- Comparative Evaluation of Seven Tigecycline Susceptibility Testing Methods for Carbapenem-ResistantInfection and drug resistance · 2021Article
- Role of Efflux Pumps in Reduced Susceptibility to Tigecycline among Clinical Isolates ofInternational journal of applied & basic medical researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 8 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tigecycline is an alternative antibiotic for managing carbapenem-resistant Gram-negative bacterial infections. However, disk diffusion and automated testing often show false-intermediate or false-resistant results in tigecycline susceptibility, misleading clinical antimicrobial therapy. Broth microdilution (BMD) is the reference method for testing tigecycline susceptibility, but it is labor intensive and time consuming to perform in clinical laboratories. Therefore, a simple and accurate method is urgently needed. We evaluated the performance of VITEK 2, E-test, Kirby-Bauer disk diffusion (KB), and modified KB disk diffusion (mKB) versus BMD in testing tigecycline susceptibility of 372 strains of carbapenem-resistant Klebsiella pneumoniae (CRKP) and 346 strains of carbapenem-resistant Acinetobacter baumannii (CRAB). BMD confirmed that 96.8% of CRKP and 91% of CRAB strains were susceptible to tigecycline. E-test, VITEK 2, KB, and mKB yielded categorical agreement of 96.7/59.3%, 69.9/54.3%, 78.5/87.3%, and 96.5%/91% for CRKP/CRAB, respectively. No very major error was found for either CRKP or CRAB by any method. No major error was found for CRKP or CRAB by the mKB method. The mKB method enhanced by R-buffer is simple, accurate, and inexpensive for clinical laboratories to test the susceptibility of CRKP and CRAB isolates to tigecycline.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.